NEW YORK (GenomeWeb News) – PrognosDx Health and the Molecular Medicine Research Institute announced recently a broad collaborative R&D agreement aimed at using PrognosDx's technology for the development of a new class of epigenetic therapeutics.

The deal provides Palo Alto, Calif.-based PrognosDx with resources to launch CLIA lab services, including a prostate cancer prognosis test and predictive tests for other cancers, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.